Cibinqo

(abrocitinib) Pfizer

Composition^3,4:

• Cibinqo Tablets: 50 mg, 100 mg, and 200 mg

Indications^3,4:

Cibinqo is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

References:

3. Drug Office. Department of Health, HKSAR. https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/141193 (accessed on 27 Jan 2023) 

4. Cibinqo (abrocitinib). US Prescribing Information 2022.